Grifols (NASDAQ:GRFS) Issues Quarterly Earnings Results

Grifols (NASDAQ:GRFS) posted its quarterly earnings data on Tuesday. The biotechnology company reported $0.02 earnings per share for the quarter, missing analysts’ consensus estimates of $0.23 by ($0.21), reports. The company had revenue of $1.96 billion for the quarter. Grifols had a return on equity of 1.73% and a net margin of 0.90%. Grifols updated its FY 2024 guidance to EPS.

Grifols Trading Up 2.3 %

Shares of NASDAQ GRFS traded up $0.17 during mid-day trading on Thursday, hitting $7.64. 2,818,213 shares of the company were exchanged, compared to its average volume of 2,274,393. The company has a debt-to-equity ratio of 1.26, a current ratio of 2.79 and a quick ratio of 1.29. The stock has a 50 day simple moving average of $7.39 and a 200-day simple moving average of $7.27. Grifols has a 1-year low of $5.30 and a 1-year high of $12.15.

Institutional Trading of Grifols

Hedge funds and other institutional investors have recently made changes to their positions in the company. Capital World Investors boosted its stake in shares of Grifols by 4.9% in the first quarter. Capital World Investors now owns 20,749,225 shares of the biotechnology company’s stock valued at $138,605,000 after buying an additional 961,700 shares in the last quarter. Brandes Investment Partners LP grew its stake in shares of Grifols by 22.2% during the 4th quarter. Brandes Investment Partners LP now owns 13,516,011 shares of the biotechnology company’s stock worth $156,245,000 after purchasing an additional 2,454,730 shares during the period. First Trust Advisors LP increased its holdings in shares of Grifols by 6.9% in the 4th quarter. First Trust Advisors LP now owns 4,684,749 shares of the biotechnology company’s stock valued at $54,156,000 after purchasing an additional 302,380 shares in the last quarter. Norges Bank acquired a new stake in shares of Grifols in the fourth quarter valued at about $26,137,000. Finally, Sei Investments Co. boosted its holdings in Grifols by 5.3% during the first quarter. Sei Investments Co. now owns 2,109,416 shares of the biotechnology company’s stock worth $14,091,000 after buying an additional 107,000 shares in the last quarter.

About Grifols

Grifols, SA operates as a plasma therapeutic company in Spain, the United States, Canada, and internationally. The company provides immunoglobulin to treat immunodeficiencies; albumin used to restore circulatory volume and protein loss in pathophysiological conditions, such as liver cirrhosis, cardiocirculatory failure, trauma and severe burns; alpha-1 proteinase inhibitor, a plasma protein, used to treat a genetic disease known as alpha-1; factorVIII/von Willerbrand factor and factor IX, clotting factors for the treatment of hemophilia A and von Willebrand's disease, as well as hemophilia B; antithrombin III to treat hereditary antithrombin deficiency; Fostamatinib, a spleen tyrosine kinase inhibitor; combination of fibrinogen and enzyme thrombin that acts as a biological sealant to control surgical bleeding; and plasma exchange with albumin used to treat Alzheimer's disease.